The University of Southampton
University of Southampton Institutional Repository

Plasma inhibitory activity against tumor necrosis factor in fulminant hepatic failure

Plasma inhibitory activity against tumor necrosis factor in fulminant hepatic failure
Plasma inhibitory activity against tumor necrosis factor in fulminant hepatic failure
1. Soluble tumour necrosis factor receptors released into the circulation inhibit the effects of excess tumour necrosis factor-alpha and represent an important protective response. 2. In this study we have measured the levels of tumour necrosis factor and soluble tumour necrosis factor receptors p55 and p75 in the plasma of 10 patients with fulminant hepatic failure and 10 healthy control subjects. The capacity of the plasmas at varying dilutions to inhibit the biological activity of 1000 pg/ml of recombinant tumour necrosis factor in a tumour necrosis factor cytotoxicity assay in vitro was also determined. 3. The mean plasma levels of tumour necrosis factor in patients with fulminant hepatic failure (48.4 +/- 10.9 pg/ml) were significantly increased compared with normal control subjects (6.1 +/- 1.04 pg/ml, P < 0.01). Plasma soluble tumour necrosis factor receptors p55 and p75 were also significantly elevated in patients with fulminant hepatic failure (18.16 +/- 9.94 ng/ml and 16.06 +/- 9.93 ng/ml respectively) when compared with normal control subjects (1.28 +/- 0.24 ng/ml and 1.62 +/- 0.91 ng/ml, P < 0.001). 4. Fulminant hepatic failure plasma had a much lower capacity to inhibit tumour necrosis factor bioactivity in vitro, with a statistically significant difference between the inhibitory capacity of the fulminant hepatic failure and normal plasma seen at plasma dilutions of 1:5 and 1:20 (P < 0.05). 5. The reduced tumour necrosis factor neutralization capacity observed in fulminant hepatic failure, despite the increased levels of soluble tumour necrosis factor receptors, suggests enhanced susceptibility to the potential deleterious effects of tumour necrosis factor in fulminant hepatic failure.
0143-5221
77-80
Keene, H.M.
4dd82fcb-2524-4856-9f8e-6320ef5bfc2d
Sheron, N.
cbf852e3-cfaa-43b2-ab99-a954d96069f1
Goka, J.
157fa443-649d-4054-95f9-f754d9048074
Hughes, R.D.
8a9b2db0-e2da-4266-8fe5-06b371fbe6aa
Williams, R.
49181762-00c1-4043-9247-a9bcddbd04f7
Keene, H.M.
4dd82fcb-2524-4856-9f8e-6320ef5bfc2d
Sheron, N.
cbf852e3-cfaa-43b2-ab99-a954d96069f1
Goka, J.
157fa443-649d-4054-95f9-f754d9048074
Hughes, R.D.
8a9b2db0-e2da-4266-8fe5-06b371fbe6aa
Williams, R.
49181762-00c1-4043-9247-a9bcddbd04f7

Keene, H.M., Sheron, N., Goka, J., Hughes, R.D. and Williams, R. (1996) Plasma inhibitory activity against tumor necrosis factor in fulminant hepatic failure. Clinical Science, 90 (1), 77-80.

Record type: Article

Abstract

1. Soluble tumour necrosis factor receptors released into the circulation inhibit the effects of excess tumour necrosis factor-alpha and represent an important protective response. 2. In this study we have measured the levels of tumour necrosis factor and soluble tumour necrosis factor receptors p55 and p75 in the plasma of 10 patients with fulminant hepatic failure and 10 healthy control subjects. The capacity of the plasmas at varying dilutions to inhibit the biological activity of 1000 pg/ml of recombinant tumour necrosis factor in a tumour necrosis factor cytotoxicity assay in vitro was also determined. 3. The mean plasma levels of tumour necrosis factor in patients with fulminant hepatic failure (48.4 +/- 10.9 pg/ml) were significantly increased compared with normal control subjects (6.1 +/- 1.04 pg/ml, P < 0.01). Plasma soluble tumour necrosis factor receptors p55 and p75 were also significantly elevated in patients with fulminant hepatic failure (18.16 +/- 9.94 ng/ml and 16.06 +/- 9.93 ng/ml respectively) when compared with normal control subjects (1.28 +/- 0.24 ng/ml and 1.62 +/- 0.91 ng/ml, P < 0.001). 4. Fulminant hepatic failure plasma had a much lower capacity to inhibit tumour necrosis factor bioactivity in vitro, with a statistically significant difference between the inhibitory capacity of the fulminant hepatic failure and normal plasma seen at plasma dilutions of 1:5 and 1:20 (P < 0.05). 5. The reduced tumour necrosis factor neutralization capacity observed in fulminant hepatic failure, despite the increased levels of soluble tumour necrosis factor receptors, suggests enhanced susceptibility to the potential deleterious effects of tumour necrosis factor in fulminant hepatic failure.

This record has no associated files available for download.

More information

Published date: 1996

Identifiers

Local EPrints ID: 79610
URI: http://eprints.soton.ac.uk/id/eprint/79610
ISSN: 0143-5221
PURE UUID: 558da99c-720c-419b-89bf-c996141dae26
ORCID for N. Sheron: ORCID iD orcid.org/0000-0001-5232-8292

Catalogue record

Date deposited: 17 Mar 2010
Last modified: 23 Feb 2023 17:42

Export record

Contributors

Author: H.M. Keene
Author: N. Sheron ORCID iD
Author: J. Goka
Author: R.D. Hughes
Author: R. Williams

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×